ADMA logo

ADMA Biologics (ADMA) Company Overview

Profile

Full Name:

ADMA Biologics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

October 17, 2013

Indexes:

Not included

Description:

ADMA Biologics is a biotechnology company that develops and produces specialty plasma-derived therapies. They focus on treating immune deficiencies and infectious diseases, using human plasma to create products that help patients with serious health conditions. Their goal is to improve patient outcomes through innovative treatments.

Key Details

Price

$16.80

Annual Revenue

$426.45 M(+65.15% YoY)

Annual EPS

$0.81(+723.08% YoY)

Beta

1.60

Events Calendar

Earnings

Next earnings date:

May 9, 2025

Recent quarterly earnings:

Mar 3, 2025

Recent annual earnings:

Mar 3, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Mar 4, 25 Cantor Fitzgerald
Overweight
Nov 8, 24 Raymond James
Strong Buy
Nov 8, 24 HC Wainwright & Co.
Buy
Oct 14, 24 HC Wainwright & Co.
Buy
Sep 20, 24 Cantor Fitzgerald
Overweight
Aug 12, 24 HC Wainwright & Co.
Buy
Aug 9, 24 Cantor Fitzgerald
Overweight
Jul 9, 24 Cantor Fitzgerald
Overweight
Jun 20, 24 Mizuho
Buy
May 10, 24 Raymond James
Strong Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for ADMA Biologics?
  • Does ADMA Biologics pay dividends?
  • What sector is ADMA Biologics in?
  • What industry is ADMA Biologics in?
  • What country is ADMA Biologics based in?
  • When did ADMA Biologics go public?
  • Is ADMA Biologics in the S&P 500?
  • Is ADMA Biologics in the NASDAQ 100?
  • Is ADMA Biologics in the Dow Jones?
  • When was ADMA Biologics's last earnings report?
  • When does ADMA Biologics report earnings?
  • Should I buy ADMA Biologics stock now?

What is the ticker symbol for ADMA Biologics?

The ticker symbol for ADMA Biologics is NASDAQ:ADMA

Does ADMA Biologics pay dividends?

No, ADMA Biologics does not pay dividends

What sector is ADMA Biologics in?

ADMA Biologics is in the Healthcare sector

What industry is ADMA Biologics in?

ADMA Biologics is in the Biotechnology industry

What country is ADMA Biologics based in?

ADMA Biologics is headquartered in United States

When did ADMA Biologics go public?

ADMA Biologics's initial public offering (IPO) was on October 17, 2013

Is ADMA Biologics in the S&P 500?

No, ADMA Biologics is not included in the S&P 500 index

Is ADMA Biologics in the NASDAQ 100?

No, ADMA Biologics is not included in the NASDAQ 100 index

Is ADMA Biologics in the Dow Jones?

No, ADMA Biologics is not included in the Dow Jones index

When was ADMA Biologics's last earnings report?

ADMA Biologics's most recent earnings report was on Mar 3, 2025

When does ADMA Biologics report earnings?

The next expected earnings date for ADMA Biologics is May 9, 2025

Should I buy ADMA Biologics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions